AbstractObjective To compare different non-operative clinical staging criteria regarding their accuracy and feasibility in evaluation of patients with esophageal squamous cell carcinoma (ESCC) receiving concurrent intensity-modulated radiotherapy (IMRT) and chemotherapy. Methods A study was performed on clinical data from 242 ESCC patients who received concurrent IMRT and chemotherapy in our hospital from 2008 to 2014. Prognostic prediction was compared between the Chinese 2009 staging system, the 6th edition staging system, and a suggested staging system. The survival rates were calculated by the Kaplan-Meier method and analyzed by the log-rank test. A prognostic analysis was made by the Cox model. ResultsThe 3-year sample size and overall survival rate were 168 and 47.4%, respectively. Esophageal tumor volume and the maximum diameter of metastatic lymph nodes were prognostic factors (P=0.000,0.000). An intersection of T3 and T4 survival curves was found in the Chinese staging system and the 6th version staging system (P=0.696,0.594), while an intersection of N1 and N2 survival curves was found in the Chinese staging system (P=0.068). The T staging based on esophageal tumor volume, N staging based on the maximum diameter of metastatic lymph nodes, and their combination could achieve a good separation of survival curves of different stages (P=0.000,0.000,0.000). Conclusions The T staging based on esophageal tumor volume combined with the N staging based on the maximum diameter of metastatic lymph nodes is an convenient non-operative clinical staging approach for prognostic prediction of ESCC patients receiving concurrent IMRT and chemotherapy.
Chen Junqiang,Lin Yu,Su Tingfeng et al. Clinical study of non-operative staging of esophageal squamous cell carcinoma underwent intensity-modulated radiotherapy combined with chemotherapy[J]. Chinese Journal of Radiation Oncology, 2017, 26(2): 155-159.
Chen Junqiang,Lin Yu,Su Tingfeng et al. Clinical study of non-operative staging of esophageal squamous cell carcinoma underwent intensity-modulated radiotherapy combined with chemotherapy[J]. Chinese Journal of Radiation Oncology, 2017, 26(2): 155-159.
[1] Nomura M,Shitara K,Kodaira T,et al. Prognostic impact of the 6th and 7th American joint committee on cancer TNM staging systems on esophageal cancer patients treated with chemoradiotherapy[J].Int J Radiat Oncol Biol Phys,2012,82(2):946-952.DOI:10.1016/j.ijrobp.2010.12.045. [2] 刘晓,王贵齐,贺舜,等.探讨非手术食管癌临床分期有效性与预测预后价值[J].中华放射肿瘤学杂志,2014,23(1):17-22.DOI:10.3760/cma.j.issn.1004-4221.2014.01.005. Liu X,Wang GQ,He S,et al. Efficacy and predictive value of clinical stage in non-surgical patients with esophageal cancer[J].Chin J Radiat Oncol,2014,23(1):17-22.DOI:10.3760/cma.j.issn.1004-4221.2014.01.005. [3] Wittekind C,Compton CC,Greene FL,et al. TNM residual tumor classification revisited[J].Cancer,2002,94(9):2511-2516.DOI:10.1002/cncr.10492. [4] 中国非手术治疗食管癌临床分期专家小组.非手术治疗食管癌的临床分期标准(草案)[J].中华放射肿瘤学杂志,2010,19(3):179-180.DOI:10.3760/cma.j.issn.1004-4221.2010.03.001.Expert group on clinical staging of non surgical treatment of esophageal cancer in China. Clinical staging criteria for non-surgical treatment of esophageal cancer (Draft)[J].Chin J Radiat Oncol,2010,19(3):179-180.DOI:10.3760/cma.j.issn.1004-4221.2010.03.001. [5] 苏婷凤,陈俊强,林宇,等.同步放化疗治疗中晚期食管癌的预后影响因素分析[J].肿瘤研究与临床,2015,27(6):385-388,393.DOI:10.3760/cma.j.issn.1006-9801.2015.06.006. Su TF,Chen JQ,Lin Y,et al. Analysis of prognostic factors of advanced esophageal carcinoma with concurrent radiotherapy and chemotherapy[J].Cancer Res China,2015,27(6):385-388,393.DOI:10.3760/cma.j.issn.1006-9801.2015.06.006. [6] 郭梅,赵一电,杨海军,等.食管肿瘤5 406例临床病理特点对比分析[J].中华肿瘤防治杂志,2008,15(1):54-56.DOI:10.3969/j.issn.1673-5269.2008.01.015. Guo M,Zhao YD,Yang HJ,et al. Analysis of clinicopathological characteristics for 5 406 cases of esophageal neoplasm[J].Chin J Cancer Prev Treat,2008,15(1):54-56.DOI:10.3969/j.issn.1673-5269.2008.01.015. [7] Siewert JR,Stein HJ,Feith M,et al. Histologic tumor type is an independent prognostic parameter in esophageal cancer:lessons from more than 1,000 consecutive resections at a single center in the Western world[J].Ann Surg,2001,234(3):360369. [8] Cooper JS,Guo MD,Herskovic A,et al. Chemoradiotherapy of locally advanced esophageal cancer:long-term follow-up of a prospective randomized trial (RTOG 85-01).Radiation Therapy Oncology Group[J].JAMA,1999,281(17):1623-1627. [9] Freilich J,Hoffe SE,Almhanna K,et al. Comparative outcomes for three-dimensional conformal versus intensity-modulated radiation therapy for esophageal cancer[J].Dis Esophagus,2015,28(4):352-357.DOI:10.1111/dote.12203. [10] Tang HR,Ma HF,An SM,et al. A phase Ⅱ study of concurrent chemoradiotherapy with paclitaxel and cisplatin for inoperable esophageal squamous cell carcinoma[J].Am J Clin Oncol,2016,39(4):3509-354.DOI:10.1097/coc.0000000000000069. [11] 许茜,刘志坤,曹彦坤,等.食管癌大体肿瘤靶区体积与淋巴结转移及预后的关系[J].中华肿瘤杂志,2012,34(9):684-687.DOI:10.3760/cma.j.issn.0253-3766.2012.09.009. Xu Q,Liu ZK,Cao YK,et al. Relationship of gross tumor volume with lymph node metastasis and prognosis of esophageal carcinoma[J].Chin J Oncol,2012,34(9):684-687.DOI:10.3760/cma.j.issn.0253-3766.2012.09.009. [12] 祝淑钗,么伟楠,李娟,等.食管癌非手术治疗临床分期新标准的对比研究[J].中华放射肿瘤学杂志,2016,25(2):109-113.DOI:10.3760/cma.j.issn.1004-4221.2016.02.005. Zhu SC,Yao WN,Li J,et al. A comparative study of new clinical staging systems for esophageal carcinoma treated with non-surgical therapy[J].Chin J Radiat Oncol,2016,25(2):109-113.DOI:10.3760/cma.j.issn.1004-4221.2016.02.005. [13] 陈建洲,陈创珍,李德锐,等.非手术治疗食管癌临床分期的验证[J].中国肿瘤,2012,21(5):374-378. Chen JZ,Chen CZ,Li DR,et al. Verification of non-surgical clinical staging for esophageal carcinoma[J].China Cancer,2012,21(5):374-378. [14] 李娟,祝淑钗,刘志坤,等.食管癌三维适形放疗GTV-T体积与临床分期及预后的相关性分析[J].肿瘤防治研究,2015,42(7):693-696.DOI:10.3971/j.issn.1000-8578.2015.07.011. Li J,Zhu SC,Liu ZK,et al. Correlation between GTV-T volume,clinical stage and prognosis of esophageal carcinoma patients treated with three-dimensional conformal radiotherapy[J].Cancer Res Prev Treat,2015,42(7):639-696.DOI:10.3971/j.issn.1000-8578.2015.07.011.
2017, Vol. 26 
